2599708 Ontario Inc. (“Good & Green”) is pleased to announce its comprehensive commitment to Corporate Social Responsibility (“CSR”).
“Good & Green is pleased to be a leader in the cannabis industry with its firm commitment to CSR. Good & Green strongly believes that CSR should be at the core of any cannabis company,” said Jeannette VanderMarel, co-founder and President of Good & Green. “As a social responsible company, Good & Green will consider all stakeholders in its decision-making and actions. It also means that Good & Green, while seeking profits, will balance the values to be gained against the costs of achieving the benefits.”
“Good & Green has placed CSR at the centre of how it conducts its business as well as manages policy and procedures to produce an overall positive impact on society. This is also reflected in Good & Green’s mission statement: We will make a difference in the cannabis industry, by being a best-in-class, socially responsible, customer-focused and profitable Licensed Producer of cannabis,” said Daniel Goldberg, co-founder and Chief Executive Officer of Good & Green.
Good & Green’s CSR commitment outlines Good & Green’s purpose, approach and key priorities, in addition to outlining how the company will work towards achieving these goals. Good & Green’s purpose, approach and priorities will be at the core of all employees’ actions. Good & Green will ensure that its vendors and suppliers adhere to a similarly high standard. Good & Green’s approach to CSR recognizes that corporate decisions can affect society and that Good & Green must continually demonstrate responsible practices in a respectful, ethical and fully accountable manner, keeping in mind the best interest of its stakeholders.
- Our Purpose: Good & Green’s purpose is to make a positive impact on the community, provide corporate and community leadership, be transparent and inclusive, employ best practices, be trusted and respected, and consider all stakeholders as part of the company’s decision making.
- Our Approach: The pillars of Good & Green’s approach will include its policies and procedures, code of conduct, corporate governance structure, partnerships, stakeholder engagement, and CSR reporting. These items will ensure the company is always focused on and committed to its responsibilities to its stakeholders.
- Our Priorities: Good & Green’s key CSR priorities include responsible production, creating a safe and diverse workplace, improving our community, upholding the highest standards within our supply chain, and protecting the environment by minimizing energy consumption and waste.
Good & Green’s CSR priorities, are in alignment with the company’s goal to become a best-in class industry leader, encourage responsible consumption, keep product out of the hands of children and ensure the safety and security of communities around us. For additional information on Good & Green’s commitment to CSR as well as further details on its priorities, please visit www.goodandgreen.com/csr.
About Good & Green
Good & Green is a socially responsible, organic cannabis company co-founded by Jeannette VanderMarel (co-founder The Green Organic Dutchman) and Daniel Goldberg (formerly PharmaCan, Macquarie, CIBC, and National Bank). The company is focused on developing high quality, consistent, homogeneous organic cannabis and cannabis products. Good & Green received its Cultivation License from Health Canada in October 2018 and operates from its 46,000 square foot facility situated on five acres of land in Brantford, Ontario. Good & Green also owns a 100 acre farm in southwest Ontario and will be applying for a second site license in October 2018. The farm is capable of producing at least 40,000 kg of dried cannabis, and the company anticipates beginning production in the early spring of 2019.
The Corporation’s Advisory Panel includes Trina Fraser (Partner, Brazeau Seller LLP), Steve Kroft (CEO, Conviron), Anita Wortzman (President, Farmers Edge), and Dr. Gillian Davidson (CEO, Wild Horse Consulting Ltd.).
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.